What antiviral medications and dosing are recommended for prophylaxis and treatment in an otherwise healthy adult after exposure to influenza A?

Antiviral Medications for Influenza A Exposure in Healthy Adults

For an otherwise healthy adult exposed to influenza A, use oseltamivir 75 mg once daily for 7 days after the most recent exposure, starting within 48 hours of exposure. 1, 2

Post-Exposure Prophylaxis Recommendations

Drug Selection

Neuraminidase inhibitors (NAIs) are the only recommended agents for influenza A prophylaxis. Specifically:

• Oseltamivir 75 mg once daily (oral) 1, 2, 3
• Zanamivir 10 mg once daily (inhaled) 1, 2, 3

Adamantanes (amantadine and rimantadine) should not be used due to widespread resistance among circulating influenza A strains 1, 2.

Timing and Duration

• Start within 48 hours of exposure for maximum efficacy 2, 3
• Continue for 7 days after the most recent known exposure in household settings 1, 2
• If >48 hours have elapsed since exposure, do not start prophylaxis; instead, educate the patient to initiate full-dose treatment immediately if symptoms develop 2

Efficacy

Post-exposure prophylaxis with oseltamivir demonstrates:

• 58.5% protective efficacy in household contacts 4
• 68-89% efficacy in contacts of index cases 4
• Zanamivir shows comparable efficacy 3

Treatment Recommendations (If Symptoms Develop)

If the exposed individual develops symptoms while on prophylaxis or within the exposure window:

Drug and Dosing

• Oseltamivir 75 mg twice daily for 5 days 1, 2
• Zanamivir 10 mg (2 inhalations) twice daily for 5 days 1

Critical Timing

• Initiate within 48 hours of symptom onset for optimal benefit 1, 5, 2
• Treatment reduces illness duration by approximately 1 day in otherwise healthy adults 6, 5, 4

Important Consideration

If the patient was receiving prophylaxis and develops symptoms, switch to treatment dosing and consider testing for influenza to guide further management 2. Ideally, switch to an antiviral with a different resistance profile if available and not contraindicated 2.

Key Clinical Pitfalls

Common Mistakes to Avoid

1. Do not use adamantanes (amantadine/rimantadine) - resistance rates make them ineffective for current influenza A strains 1, 2
2. Do not delay beyond 48 hours - prophylaxis efficacy drops significantly after this window 2, 3
3. Do not confuse prophylaxis and treatment dosing - prophylaxis is once daily, treatment is twice daily for oseltamivir 1
4. Do not use zanamivir in patients with underlying airway disease (asthma, COPD) due to risk of bronchospasm 6

Special Populations

• Renal impairment: Reduce oseltamivir dose to 75 mg once daily if creatinine clearance <30 mL/min 1
• Pregnancy: Oseltamivir can be used, though data are limited; potential benefits typically outweigh risks 6

Prophylaxis vs. Vaccination

Antiviral prophylaxis is not a substitute for influenza vaccination 7, 6. Vaccination remains the primary prevention strategy. Prophylaxis serves as an adjunct in specific exposure situations, particularly when:

• Exposure occurs before vaccine-induced immunity develops
• The exposed individual is unvaccinated
• There is poor vaccine-strain match with circulating viruses

Resistance Considerations

While neuraminidase inhibitors remain effective, sporadic oseltamivir resistance has been documented, particularly in:

• Immunocompromised patients with prolonged viral replication 1
• Patients developing illness while on prophylaxis 1

However, >99% of circulating influenza viruses remain susceptible to oseltamivir 1, making it the preferred first-line agent for otherwise healthy adults.